근골격계 통증 : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(주요 32개 시장, 2025-2035년)

Global Musculoskeletal Pain Market Outlook

Thelansis's "Global Musculoskeletal Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Musculoskeletal Pain treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Musculoskeletal Pain Overview

Musculoskeletal pain is the most prevalent pain category globally, encompassing acute and chronic conditions arising from bones, joints, muscles, and connective tissues. Driven by nociceptive, neuropathic, and nociplastic pathways, its development and chronicity are heavily influenced by biopsychosocial elements like sleep disruption, psychological distress, and coping strategies. Diagnosis is primarily clinical, guided by physical examination, validated tracking tools, and targeted imaging. Modern management prioritizes active interventions like tailored exercise and physiotherapy over passive treatment. Standard pharmacological care combines baseline non-steroidal anti-inflammatory drugs and duloxetine with landmark new precision therapeutics. For widespread nociplastic pain like fibromyalgia, management includes newly approved sublingual cyclobenzaprine. For acute trauma or severe musculoskeletal injury, the clinical workflow is transformed by suzetrigine, a novel non-addictive peripheral sodium channel inhibitor that reduces reliance on opioids. Cognitive behavioral therapy and pain neuroscience education are leveraged to address central sensitization, while interventional procedures are reserved for highly selective structural causes. Early patient empowerment is critical to maximize long-term functional recovery and enhance quality of life.

Key Highlights

• In Germany, the prevalent Musculoskeletal Pain population is projected to increase from 12,474,885 in 2025 to 13,112,853 by 2035.
• Musculoskeletal Pain is a leading cause of chronic pain, disability, and reduced quality of life worldwide.
• Current treatment options primarily provide symptomatic relief, with many patients experiencing persistent pain.
• Significant unmet need remains for therapies that provide long-term pain control while improving function and mobility.

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle Ea

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)